The abstract is read at the publisher; the summary is JClub's.
Sotagliflozin attenuates platelet activation and thrombus formation in ex vivo blood and in vivo mouse models, whereas empagliflozin shows minor to no effects.
- Why it matters: Cardiovascular benefits seen with sotagliflozin in T2DM patients at high risk need mechanistic explanation, particularly regarding platelet-driven thrombosis.
- What they did: The study tested platelet activation and thrombus formation using ex vivo blood from healthy donors or T2DM patients and in vivo mouse models, comparing sotagliflozin with empagliflozin. It also used Slc5a1fl/fl Gp1ba-Cre mice with platelet-specific SGLT1 deletion.
- The result: Sotagliflozin inhibited platelet activity and thrombus formation without impacting hemostasis, and platelet-specific SGLT1 deletion reduced integrin activation and thrombus formation. This suggests SGLT1 involvement may contribute to sotagliflozin’s cardiovascular protection relative to empagliflozin.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.